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Abstract
Our current state of knowledge on noninvasive positive pressure ventilation (NPPV) and
technical aspects are discussed in the present review. In patients with chronic obstructive
pulmonary disease, NPPV can be considered a valid therapeutic option to prevent
endotracheal intubation. Evidence suggests that, before eventual endotracheal intubation,
NPPV should be considered as first-line intervention in the early phases of acute
exacerbation of chronic obstructive pulmonary disease. Small randomized and non-
randomized studies on the application of NPPV in patients with acute hypoxaemic
respiratory failure showed promising results, with reduction in complications such as
sinusitis and ventilator-associated pneumonia, and in the duration of intensive care unit stay.
The conventional use of NPPV in hypoxaemic acute respiratory failure still remains
controversial, however. Large randomized studies are still needed before extensive clinical
application in this condition.
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ARF = acute respiratory failure; BiPAP = bilevel positive airway pressure; COPD = chronic obstructive pulmonary disease; FiO2, fractional inspired
oxygen; NPPV = noninvasive positive pressure ventilation; PaO2, arterial partial oxygen tension; PaCO2, arterial partial carbon dioxide tension;
PEEP = positive end-expiratory pressure; PSV = pressure support ventilation.
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Introduction
Mechanical ventilation through an endotracheal tube is a
well established, accepted and life-saving procedure for
patients with acute respiratory failure (ARF). In mechani-
cally ventilated patients, however, endotracheal intubation
is the single most important predisposing factor for devel-
oping nosocomial bacterial pneumonia and infections
[1,2] and increases the risk for sinusitis. Placement and
maintenance of endotracheal tube increases patient’s dis-
comfort and stress, and often necessitates administration
of sedative agents. Endotracheal intubation may also
cause injuries and ulcerations of the tracheal mucosa that
is in contact with tube’s cuff, inducing inflammation,
oedema and submucosal haemorrhage. These conditions
represent the pathological basis of other complications,
such as airway stenosis [3,4].
Noninvasive positive pressure ventilation (NPPV) is the
delivery of assisted mechanical ventilation without the
need for an invasive artificial airway [1]. It is a safe and
effective means of improving gas exchange in patients
with many forms of ARF [5]. For example, in patients with
acute exacerbation of chronic obstructive pulmonary
disease (COPD) and hypercapnic respiratory failure,
adding noninvasive ventilation to standard therapy
decreased the need for endotracheal intubation [6–13],Critical Care    Vol 4 No 1 Antonelli and Conti
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and could reduced mortality [12]. Similarly, noninvasive
continuous positive airway pressure was effective in
patients with cardiogenic pulmonary oedema, particularly
in those with hypercapnia [14–16]. This therapy also
decreased the rates of intubation and complications [5]
and improved survival in patients with various forms of
acute hypoxaemic respiratory failure (pneumonia, conges-
tive hearth failure, chest wall impairment, etc) [17,18].
In patients with acute hypoxaemic respiratory failure,
NPPV is as effective as conventional ventilation, delivered
through an endotracheal tube, in improving gas exchange
[5]. The technique of NPPV is flexible and can be applied
both continuously and intermittently, allows speech and
swallowing, and is accepted well by patients.
Materials and techniques
An alert and cooperative patient is essential for initiating
NPPV or mask continuous positive airway pressure.
Table 1 summarizes the characteristics of appropriate
patients. During NPPV, patients must be able to synchro-
nize respiratory efforts voluntarily with those of the ventila-
tor. COPD hypercapnic patients with narcosis may
represent an exception. Alertness in the majority of these
patients is improved within 15–30 min. During NPPV,
patients can achieve a level of control and independence
that is totally different from when they are intubated, and
sedation is infrequently required. However, it should be
avoided in patients with severe hypotension or life-threaten-
ing arrhythmia, and in those who require an endotracheal
tube to protect the airways (coma, impaired swallowing,
etc; Table 1). Patients who have refractory hypoxaemia
[arterial partial oxygen tension (PaO2)/fractional inspired
oxygen (FiO2) £ 60], morbid obesity (>200% of ideal body
weight) or with unstable angina or acute myocardial infarc-
tion should be closely managed by experienced personnel
[5,19]. Criteria for NPPV discontinuation and endotracheal
intubation must be thoroughly taken into account in order
to avoid dangerous delays (Table 2).
Interface
NPPV can be administered both with nasal and full-face
masks. The nasal mask is usually well tolerated because it
causes less claustrophobia and discomfort. It allows
eating, drinking and expectorating. Conversely, a facial
mask is preferable in severe respiratory failure, because
dyspneic patients breath through the mouth in order to
bypass resistance of the nasal passages, and mouth
opening during nasal mask ventilation results in air leakage
and decreased effectiveness [20,21]. Masks are firmly
secured with elastic straps (Fig. 1) to the face in order to
avoid air leaks and consequent malfunction. The dead
space volumes of a facial and a nasal mask are 250 ml
and 105 ml, respectively [22]. Dead space volume from
the mask and the oropharynx may affect the effectiveness
of ventilation.
In mild forms of ARF, a nasal mask could be tried first,
switching to a facial mask if necessary. Among 12 patients
(11 with COPD and one with pneumonia) with ARF who
failed NPPV with a conventional facial or nasal mask (due
to leaks or discomfort), switching to the new full-face mask
improved gas exchange and avoided endotracheal intuba-
tion in 84% of the patients [23]. A mask with transparent
dome is preferred because it allows visual monitoring of
the oral airway for the presence of secretions (Fig. 1). The
mask should be lightweight to aid in its application and
have a soft, pliable, adjustable seal to reduce trauma and
leaking [24]. The mask is secured with head straps
(Fig. 1). In our experience, skin necrosis occurs in 7% of
patients treated with NPPV for periods exceeding 72 h;
after discontinuation of NPPV, however, rapid healing of
the dermal lesions is observed, usually in 7–10 days. The
correct approach to limit these lesions is to place adhe-
sive dressings to the points of major pressure (usually the
bridge of the nose) to increase the pressure dissipation
surface and reduce the depth of skin necrosis.
Table 1
Criteria for selection of patients for noninvasive positive
pressure ventilation
Conscious and cooperative patient (chronic obstructive pulmonary
disease patients may be an exception)
No need for urgent endotracheal intubation to protect the airways or
remove copious secretions
No acute facial trauma
No recent gastroesophageal surgery
No active gastrointestinal bleeding
No impaired swallowing
Haemodynamic and rhythm stability
Face mask adequately fitted
Table 2
Criteria for noninvasive positive pressure ventilation
discontinuation and endotracheal intubation
Mask intolerance due to pain, discomfort or claustrophobia
Inability to improve gas exchanges and/or dyspnea
Haemodynamic instability or evidence of cardiac ischaemia or
ventricular dysarrhythmia
Need for urgent endotracheal intubation to manage secretions or
protect the airways
Inability to improve mental status, within 30 min after the application of
noninvasive positive pressure ventilation, in hypercapnic, lethargic
chronic obstructive pulmonary disease patients or agitated hypoxaemic
patients17
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When a full-face mask is used and the opening pressure
of the upper oesophageal sphincter (25–30 cmH2O) [25]
is overcome, gastric distension may occur, but this is not a
common event. Some masks allow the passage of a naso-
gastric tube, protecting from the risk of aerophagia, even
at pressures above 25 cmH2O.
The mask is connected to the ventilator, in the same way
as an endotracheal tube. To prevent drying of the nasal
passages and oropharynx, a humidifier should be con-
nected, but the heater should be turned off because the
upper airways that naturally warm inspired gas are not
bypassed. As an alternative to the humidifier, we prefer to
add a heat–moisture exchanger to the ventilatory circuit in
order to ensure ‘natural’ humidification and heating, and to
reduce the risk of bacterial colonization (Fig. 1).
With NPPV, tidal volume, gas exchange, respiratory rate
and diaphragmatic activity are improved in proportion to
the amount of pressure applied [20,26]. Most NPPV
studies used pressure-limited ventilation delivered by a
broad range of ventilators. Pressure-limited ventilation
improves the efficacy of spontaneous breathing by allowing
an optimal synchrony between patient effort and delivered
assistance. Inspiration is initiated by the patient’s activation
of the inspiratory muscles and of the inspiratory glottic
abductors, with consequent widening of the glottis. During
pressure support ventilation (PSV), the patient’s effort
determines volume and duration of inspiration. Gas flow
begins after the patient’s inspiratory effort reduces pres-
sure in the inspiratory circuit of the ventilator by a predeter-
mined value, usually 1–2 cmH2O. Pressure-control
ventilation has a preset inspiratory time and respiratory
rate. It may ventilate patients with low ventilatory drive more
effectively. In comparison with volume-cycled ventilation,
pressure-limited ventilation minimizes peak inspiratory mask
pressure and air leakage. Although tidal volume may vary
as a function of the change in airway resistance and com-
pliance, this variance has been an uncommon problem in
our experience. In three comparison studies of assist-con-
trolled ventilation and PSV in patients with hypercapnic
ARF, PSV was as effective as assist-controlled ventilation
in reducing the work of breathing and improving gas
exchange [27], but was better tolerated [27,28] and asso-
ciated with fewer complications [27]. During NPPV of
stable COPD patients, flow triggering reduces the respira-
tory effort and intrinsic positive end-expiratory pressure
(PEEP) during both PSV and assist-controlled ventilation
when compared with pressure triggering [29]. No differ-
ences were found between 1 and 5 l/min flow triggers
[29]. Two reports [30,31] found nasal ventilation with
assist-controlled ventilation to be ineffective and time con-
suming in end-stage obstructive lung disease. The present
trend is to favour PSV, which has the advantage of better
patient comfort and fewer complications [27].
The initial ventilator settings are continuous positive airway
pressure 0 cmH2O and PSV 10 cmH2O; the mask is then
gently held on patient’s face until the patient is comfort-
able and in synchrony with the ventilator. FiO2 is titrated to
achieve an oxygen saturation over 90%. After the mask is
secured, continuous positive airway pressure is slowly
increased to 3–5 cmH2O, and PSV is increased to obtain
the largest (>7 ml/kg) exhaled tidal volume, a respiratory
rate below 25 breaths/min and patient comfort. These
objectives may not be achieved in patients with severe
lung disease or with a leaky interface. It is important to
recognize that excessive PSV levels can cause excessive
inflation, with consequent patient–ventilator asynchrony
and activation of expiratory muscles during inspiration
(Table 3) [32].
During the early phase of milder respiratory failure and
after an initial period of continuous administration (3–6 h
in our experience) NPPV can be intermittently applied,
with periods of 10–20 min interruption when it is not used.
For sicker patients, NPPV application has to be continu-
ous for at least 12–24 h [5,18]. Discontinuation is allowed
for short periods only when the clinical situation improves.
Aggressive physiotherapy is crucial during the periods of
NPPV discontinuation. Endotracheal intubation must be
rapidly available, when indicated (Table 2).
Applications of noninvasive positive pressure
ventilation in patients with chronic obstructive
pulmonary disease
Physiologic response
NPPV is a valid method to treat COPD patients and to
avoid endotracheal intubation [6,9,26,33,34]. In COPD
Figure 1
Patient undergoing noninvasive positive pressure ventilation. The face
mask (FM), with its soft inflatable cushion (IC), is connected to the
mechanical ventilator (not shown) through a catheter mount (CM), with
a heat–moisture exchanger (HME) included in the respiratory circuit.
The face mask is secured with elastic straps (ES).
ES
FM
HME
CM
ICpatients with acute exacerbation, the increased flow resis-
tance and the inability to complete the expiration before
inspiration results in high levels of dynamic hyperinflation.
Dynamic hyperinflation alters diaphragm geometry, and
reduces its strength and endurance. Also, minor increases
in air flow resistance (as caused by airway secretions or
bronchospasm) or an augmented ventilatory demand (as
in case of fever or infection) in this context can cause res-
piratory muscle fatigue, with rapid shallow breathing,
wasted ventilation, hypercapnia and respiratory acidosis.
The work of breathing is increased to overcome the inspi-
ratory threshold load due to auto-PEEP and to drive the
tidal volume against increased airway resistances.
The classical approach to management of exacerbated
COPD is a combination of pharmacological interventions
(bronchodilators, steroids, antibiotics and inotropes) and
low-rate oxygen. When this conservative approach is not
successful, patients are intubated and mechanically
ventilated.
NPPV is a tool to correct the increased work of breathing
and avoid intubation. The combination of PEEP and posi-
tive pressure ventilation or PSV offsets the auto-PEEP
level (eliminating the additional inspiratory load) and
reduces the work of breathing that the inspiratory muscles
must generate to produce the tidal volume. When appro-
priate levels of inspiratory pressure are delivered, tidal
volume increases and respiratory rate decreases. Under
these conditions NPPV significantly reduces arterial partial
carbon dioxide tension (PaCO2), restoring normal pH, and
induces a rapid and progressive decrease in diaphrag-
matic activity as shown by electromyography [26].
It must be remembered that the level of applied PEEP
must never exceed the amount of auto-PEEP, in order to
avoid iatrogenic increases of hyperinflation. No change in
end-expiratory volume has been reported if PEEP applied
by face-mask ventilation does not exceed the 80–90% of
the auto-PEEP [35].
Clinical results
In one of the first applications of NPPV in a small sample
of COPD patients [33], the improvements in gas
exchanges suggested the possibility of avoiding endotra-
cheal intubation altogether. In a case–control study,
Brochard et al [26] showed that this approach could
reduce both the need for endotracheal intubation and the
duration of hospital stay, with obvious economic implica-
tions. In the first randomized, prospective study on 60
COPD patients, Bott et al [6] compared NPPV adminis-
tered through nasal mask with conventional therapy as a
treatment for ARF. Patients receiving NPPV had a signifi-
cant reduction in PaCO2 and dyspnea score, and
improved survival (90 versus 70%; P<0.01).
The efficacy of NPPV in acute exacerbation of COPD was
also evaluated in a European prospective randomized mul-
ticentre study [9]. In that trial, 85 COPD patients without
cardiogenic pulmonary oedema, pneumonia or postopera-
tive ARF were randomly assigned to receive conventional
treatment (oxygen therapy plus drugs) or NPPV in addition
to conventional treatment. After 1 h, NPPV achieved a sig-
nificant improvement in gas exchange. The group of
patients randomly assigned to NPPV had a significantly
lower intubation rate (26 versus 74%; P<0.001), lower
complication rate (14 versus 45%; P<0.01), lower duration
of hospital stay (23±17 versus 35±33 days; P<0.02) and
lower mortality rate (9 versus 29%; P<0.02).
In another randomized study on 26 COPD patients that
compared NPPV delivered through nasal mask with con-
ventional treatment [11], the authors reported a reduction
in intubation rate, with a significant improvement in PaO2,
heart rate and respiratory rate in the NPPV group, even
though PaCO2 did not significantly decrease. A further
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Table 3
Proposed ventilator settings and monitoring for noninvasive positive pressure ventilation
Initial setting Treatment setting
Continuous positive airway pressure 0 cmH2O Slowly increased to 3–5 cmH2O, 
(up to 8–10 cmH2O in hypoxaemic patients)
Pressure support ventilation 10 cmH2O Increased to obtain a TVe >7 ml/kg and 
respiratory rate <25 breaths/min
Fractional inspired oxygen Titrated to achieve SAT >90% Titrated to achieve SAT >90%
Mask application Mask gently held on patient’s face, until  Secure the mask with head straps
comfort and synchrony with the ventilator 
are reached
Monitoring SAT, heart rate, respiratory rate, arterial  SAT, heart rate, respiratory rate, arterial 
pressure, electrocardiogram pressure, electrocardiogram
TVe, expiratory tidal volume; SAT, saturation of oxygen.randomized study on hypercapnic and hypoxaemic ARF
[36] suggested that early application of NPPV facilitates
improvement, decreases the need for invasive mechanical
ventilation, and decreases the duration of hospitalization.
Thirty patients were randomized to receive standard treat-
ment, or NPPV in addition to standard treatment. With
standard treatment, there was significant improvement
only in respiratory rate (P<0.05). With NPPV, PaO2
(P<0.001), PaCO2 (P<0.001), pH (P<0.001) and res-
piratory rate (P<0.001) improved significantly compared
with baseline. Duration of hospital stay for the NPPV
group was shorter (P<0.05) than that in the standard
treatment group. One patient in the NPPV group required
invasive mechanical ventilation.
Lofaso  et al [37] recently reported the risk of carbon
dioxide rebreathing with bilevel positive airway pressure
(BiPAP) ventilators when PEEP was not applied or when
the expiratory time was too short; this might partly explain
the limited PaCO2 modification noted by Kramer et al [11]
In a randomized trial in 50 patients with acute exacerba-
tion of COPD, noninvasive PSV during weaning reduced
weaning time (P=0.021), shortened the duration of stay
in the intensive care unit (P=0.005), decreased the inci-
dence of nosocomial pneumonia, and improved 60-day
survival rates (P=0.009) [34].
Noninvasive positive pressure ventilation in
patients with acute respiratory failure
Physiologic response
Following the good results obtained in patients with acute
exacerbations of COPD and the promising data from a
few pilot studies (retrospective or nonrandomized)
[33,38,39] in patients with ARF, NPPV is now currently
under clinical evaluation as a possible alternative to con-
ventional ventilation with endotracheal intubation and as a
means to reduce the intubation rate during ARF. NPPV is
adopted in ARF that is not related to COPD, with the aim
of decreasing the amount of spontaneous work of breath-
ing and correcting the rapid shallow breathing that is
always present in acute conditions. NPPV can prevent res-
piratory muscle fatigue and endotracheal intubation.
NPPV can be administrated via a nasal or a full-face mask.
Selection criteria and criteria for NPPV discontinuation
and endotracheal intubation are similar to those described
for COPD patients (Tables 1 and 2). In our experience and
that of others [5,25], face masks seem more appropriate
for patients affected by severe hypoxaemia, who are
usually tachypneic and breathe through the mouth.
Clinical results
Nonrandomized, noncontrolled studies
Meduri et al [33] in 1989 reported one of the first clinical
applications of NPPV in patients with ARF. In that study
PSV and pressure control ventilation were used through
face masks in four patients affected by cardiogenic and
noncardiogenic pulmonary oedema, with good results in
three. Subsequently, Pennock et al [39] reported suc-
cessful treatment in 50% of a large group of patients with
ARF of different aetiologies; promising results were
obtained in the subgroup of patients affected by postoper-
ative ARF. Similar results were achieved using noninvasive
ventilation (always through a nasal mask) in a second
study [40]. Wysocki et al [41] reported a 47% success
rate in the treatment of ARF patients.
In a study conducted on 64 patients admitted to the emer-
gency department for ARF due to cardiogenic pulmonary
oedema and pneumonia [42] there was a significant
improvement in arterial blood gases after 1 h of continu-
ous positive airway pressure ventilation. In the cardiogenic
pulmonary oedema group, PaO2 surpassed 100 mmHg
with a clear-cut improvement in PaCO2 and pH
(P<0.0001, for both parameters). In the pneumonia
group, oxygenation was also improved, but with the per-
sistence of a significant shunt. Fifty-four patients (84%)
were successfully ventilated under continuous positive
airway pressure, avoided intubation and had a favourable
prognosis, mainly in the cardiogenic pulmonary oedema
group, without side effects.
In a pilot study conducted in patients with haematologi-
cal malignancies complicated by ARF [43] 15 out of 16
individuals were successfully treated with NPPV deliv-
ered via nasal mask by means of a BiPAP ventilator
(Respironics, Pittsburgh, USA). PaO2/FiO2 and arterial
oxygen saturation significantly improved after 1 h of
treatment (P<0.01).
NPPV delivered by simplified ventilators via facial or nasal
mask can be effective for routine care, after adequate per-
sonnel training [44]. In 40 patients with hypercapnic ARF
compared with 30 matched historical patients under con-
ventional treatment, NPPV was associated with a reduc-
tion in negative events, such as endotracheal intubation,
and mortality together (17 versus 60%; P=0.0002), but
not mortality alone (5 versus 13.5%; not significant). Sig-
nificant and rapid improvements in PaCO2 and pH
between baseline and subsequent evaluations (P=0.066)
were obtained.
The utility of NPPV to prevent nosocomial pneumonia in
patients who need assisted ventilation was recently
reported in a prospective epidemiological survey on a
cohort of 320 consecutive patients, 75% of whom had
ARF not related to COPD [45]. Twenty-seven patients had
28 episodes of ventilator-associated pneumonia, but the
incidence of ventilator-associated pneumonia was
0.85/100 days of tracheal intubation and 0.16/100 days
of NPPV (P=0.004).
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more than 200 published and unpublished studies and
concluded that the addition of NPPV to standard therapy
in patients with ARF improves survival and decreases the
need for endotracheal intubation. This effect was more
evident in patients whose cause of ARF was an exacerba-
tion of COPD, however.
To assess the efficacy of NPPV in routine use, 80 patients
(aged 71±1.3 years and Acute Physiology and Chronic
Health Evaluation II score of 17.2±0.6) received BiPAP
for ARF [47]. Thirty-one of them (39%) had hypoxaemic
ARF and 25 (31%) had hypercapnic ARF; the other 24
patients (30%) suffered from ARF of varied origin. BiPAP
was successful in 80% of the patients with hypercapnic
respiratory failure, but only in 15 of the 31(48%) patients
with hypoxaemic ARF. BiPAP success was marked, with
increased PaO2/FiO2 in the hypoxaemic group, but the
risk failure was significantly greater (risk ratio 2.6, 95%
confidence interval 1.1–6.1) for patients with hypoxaemic
ARF than for those with hypercapnic respiratory failure.
Randomized studies
The first prospective randomized study dedicated to this
topic was reported by Wysocki et al [18], who randomized
41 non COPD patients with ARF to receive face-mask
mechanical ventilation versus conventional medical therapy.
NPPV reduced the need for endotracheal intubation (36
versus 100%, P=0.02), the duration of intensive care unit
stay (13±15 days versus 32±30 days; P=0.04) and mor-
tality rate (9 versus 66%; P=0.06), but only in those
patients with hypercapnia (PaCO2 >45 mmHg). No signifi-
cant differences in the hypoxaemic group without hypercap-
nia were seen. On the basis of these results, the authors
concluded that NPPV was not beneficial when used sys-
tematically in all forms of ARF not related to COPD. Kramer
et al [11] randomized 31 patients to receive nasal BiPAP or
conventional therapy for the treatment of ARF. This study
showed significant improvement in vital signs as well as
reduction in endotracheal intubation rates in the group
treated with NPPV compared with the conventionally
treated group (31 versus 73% endotracheal intubation
rates, respectively; P<0.05). Evidence from this study sup-
ported the use of NPPV in order to avoid intubation and
possibly reduce mortality, but this conclusion again applied
mainly to the subgroup of 23 (74%) patients with acute
exacerbation of COPD. Only eight patients (36%) had ARF
due to pneumonia (four patients), congestive heart failure
(two patients), asthma (one patient) or pulmonary embolism
(one patient). These studies were specifically dedicated to
evaluate NPPV as a preventive tool against endotracheal
intubation, and not as an alternative treatment for ARF.
We randomized 64 patients with hypoxaemic ARF who had
not improved with aggressive medical therapy to face-mask
NPPV or endotracheal intubation with conventional
mechanical ventilation [5]. Both groups had improvement in
the PaO2:FiO2 ratio after 1 h of ventilatory support. Ten out
of the 32 patients in the NPPV group required endotracheal
intubation. The 32 patients in the conventional ventilation
group had more frequent and serious complications (38
versus 66%; P=0.02), and pneumonia and sinusitis related
to the endotracheal tube (3 versus 31%; P=0.003).
Among the survivors, the patients in the NPPV group had a
shorter duration of mechanical ventilation (3±3 versus
6±5; P=0.006) and a shorter duration of intensive care
unit stay (6.6±5 versus 14±13 days; P=0.002). Our trial
suggested that, for patients with severe respiratory distress,
NPPV may lead to more favourable outcomes than conven-
tional ventilation, in the hands of experienced staff and in a
setting in which this technology can be rapidly and safely
administered. Furthermore a post hoc subgroup analysis
was performed for patients with a simplified acute physio-
logic score lower than 16, or 16 or greater. The 19 patients
with a simplified acute physiologic score of 16 or greater,
irrespective of group, had similar outcomes, whereas in the
45 patients with a simplified acute physiologic score lower
than 16 NPPV was superior to conventional ventilation.
Conversely, Wood et al [48] had a substantially negative
evaluation of the use of NPPV when applied in patients
with hypoxaemic ARF. These authors randomized 27
patients in the emergency department to receive conven-
tional medical therapy or NPPV for the treatment of acute
hypoxaemic respiratory failure. The 16 patients who were
randomized to the noninvasive ventilation group had a intu-
bation rate (44%) and duration of intensive care unit stay
similar to those of the 11 patients who received medical
treatment alone, but there was a trend toward a greater
rate of hospital mortality among the patients in the NPPV
group compared with patents in the conventional medical
therapy group [four patients (25%) versus none;
P=0.123]. Several factors may have influenced these neg-
ative results and may have represented biases in patient
selection. First, case mix showed an unbalanced distribu-
tion of patients with pneumonia (44% in the NPPV group
versus 12% in the conventional medical therapy group).
Second, 14% of patients had COPD. Finally, patients in
the NPPV group had a baseline PaO2 that was significantly
lower than that in the conventional medical treatment group
(59.8 versus 71.3 mmHg, respectively). Moreover, even
though the PaCO2 levels were similar in the two groups,
the range was clearly hypercapnic (around 56 mmHg in the
two groups). These differences may represent increased
severity of ARF in the NPPV group, and objective conclu-
sions are therefore difficult to make.
Noninvasive positive pressure ventilation-
assisted bronchoscopy in severely
hypoxaemic patients
Pneumonia with severe hypoxaemia is a common compli-
cation in immunocompromised patients, such as those
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or other conditions [49]. In these individuals, early diagno-
sis of the aetiological agent is paramount. Unfortunately,
severe hypoxaemia in nonintubated patients represents a
major contraindication to fiberoptic bronchoscopy and/or
bronchoalveolar lavage [50], often meaning that treatment
must be initiated on an empirical basis.
We proposed a new technique to perform fiberoptic bron-
choscopy and/or bronchoalveolar lavage in severely
hypoxaemic, nonintubated patients by means of PSV
administered through a face mask (Fig. 2) [51]. All
patients were administered NPPV for 10 min before start-
ing bronchoscopic manoeuvres and NPPV was main-
tained for at least 90 min after the procedure. In all
patients it was possible to identify the agent that caused
pneumonia, and to start an early and specific treatment.
None of the patients needed endotracheal intubation.
PaO2:FiO2 ratio and oxygen saturation increased signifi-
cantly after the application of NPPV and remained high
throughout the study.
In a recently concluded randomized study (unpublished
data) on the use of brochoalveolar lavage with or without
NPPV for the diagnosis of nosocomial pneumonia in 26
hypoxaemic patients (PaO2:FiO2 <200), we were able to
demonstrate that NPPV is more efficient than Venturi
mask in correcting hypoxaemia during brochoalveolar
lavage, but 1 h after treatment PaO2:FiO2 was not differ-
ent in the two groups.
Bronchoscopy with NPPV seems to be a feasible, safe
and effective technique to allow an early and accurate
diagnosis of pneumonia in nonintubated, severely hypox-
aemic patients. Even though good cooperation of the
patient and thorough monitoring of vital functions are
essential, the technique appears very promising for appli-
cation on a large scale in immunocompromized patients.
Conclusion
In COPD patients, NPPV can be considered as a thera-
peutic option to prevent endotracheal intubation (reducing
the additive morbidity and mortality) and to deliver artificial
ventilatory support [6,9]. When no contraindication exists,
a trial of NPPV should be always considered if a COPD
patient is observed to be in the early phase of respiratory
failure.
Some evidence suggests the utility of NPPV as a first-line
intervention in hypoxaemic ARF and for NPPV-assisted
bronchoscopy in severely hypoxaemic patients. The appli-
cation of NPPV in patients suffering from ARF not related
to COPD, despite some interesting and very promising
preliminary results [5,11], still remains controversial.
Large, prospective, randomized, multicentre studies are
therefore needed.
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